SCHEMBL10272586

SCHEMBL10272586

Cc1ccc(OCCc2ccccn2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.57
MAPT P10636 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HPGD P15428 1/20 0.51
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
TRPM8 Q7Z2W7 1/20 0.50
SYK P43405 2/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
HRH1 P35367 1/20 0.47
AURKB Q96GD4 1/20 0.47
INCENP Q9NQS7 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10697786 0.85 HRH1 (0.53) MAPTSMN1; SMN2HPGDCYP3A4CYP2D6
SCHEMBL13185257 0.83 TSHR (0.56) SMN1; SMN2HPGDCYP3A4CYP2D6CYP2C9
SCHEMBL14535234 0.83 HPGD (0.51) SMN1; SMN2HPGDCYP3A4CYP2D6CYP2C9
SCHEMBL3021299 0.83 RAB9A (0.59) MAPTSMN1; SMN2HPGDCYP3A4CYP2D6
SCHEMBL169753 0.82 SMN1; SMN2 (0.63) HIF1AMAPTSMN1; SMN2HPGDCYP3A4
SCHEMBL13166929 0.82 ALDH1A1 (0.62) SMN1; SMN2NPSR1HPGDCYP3A4CYP2D6
SCHEMBL10223301 0.82 TAS1R3 (0.50) SMN1; SMN2HPGDCYP3A4CYP2D6CYP2C9
SCHEMBL13645879 0.82 TDP1 (0.60) SMN1; SMN2NPSR1CYP3A4CYP2D6CYP2C9
SCHEMBL29278406 0.80 HPGD (0.49) SMN1; SMN2HPGDCYP3A4CYP2D6CYP2C9
SCHEMBL29278412 0.80 HPGD (0.49) HIF1ASMN1; SMN2HPGDCYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957498-B1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC (CA) 2017-02-15 EP disclosed
US-8470850-B2 Inhibitors of VEGF receptor and HGF receptor signalling METHYLGENE INC. (CA) 2013-06-25 US disclosed
US-8329726-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-12-11 US disclosed
US-20120083482-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC. 2012-04-05 US disclosed
EP-1770092-A1 Process for the preparation of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione SMITHKLINE BEECHAM PLC (GB) 2007-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083482-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING HGF, MET, KDR HIF1A 30/4885MAPT 4370/4885SMN1; SMN2 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.